Europe Clinical Trial Imaging Market

Market Overview

The Europe region is expected to reach USD 531 million by 2030 with a CAGR of 5.5%. We are living in an era of rapid advancement in our understanding of human disease.

 However, the application of this knowledge in clinical settings has not kept up with the pace of discovery. The process of developing new drugs involves a number of steps, one of which is the conduct of clinical trials. A clinical trial imaging (CTI) study is a research study in which participants participate voluntarily. Each study examines a unique scientific question concerning the usefulness of imaging technologies in detecting illness, diagnosing it, guiding treatment, or monitoring its progress. Imaging techniques for clinical trials can be broken down into the following categories: In general, screening imaging clinical trials ask questions to help researchers determine which type of imaging test will detect disease early, possibly before symptoms appear.

Clinical trials involving diagnostic imaging investigate which types of imaging tests are most likely to effectively detect disease when only a suspicion of disease exists, which types of imaging tests can assist in monitoring a known condition, and which types of imaging tests can monitor the effectiveness of a therapy to determine whether or not it is working. Image-guided interventional clinical trials are designed to evaluate the efficacy of interventions that are guided by imaging.

Imaging techniques are becoming increasingly important in the provision of evidence for decision making in oncological clinical trials. Imaging is still used to define key study end points, even though conventional morphological imaging techniques and standardised response criteria that are based on tumour size measurements have been implemented.

Market Dynamics

Europe Clinical Trial Imaging Market Drivers

The number of people requiring chronic care is increasing, which places a significant strain on Europe's healthcare systems

Life expectancy in EU countries has increased dramatically in recent decades, but many years of old age are spent living with chronic diseases and disabilities. An integrated response that places a primary emphasis on prevention across all relevant sectors is at the core of the EU's strategy for addressing the challenge posed by chronic diseases. This strategy is being implemented in tandem with efforts to strengthen health systems in order to improve chronic disease management. This problem is supposed to drive the market demand for CTI.

Europe Clinical Trial Imaging Market Restraints

Increasing financial burden associated with chronic diseases

Because of the extremely high costs involved in treating chronic diseases and the fact that the average age of populations in Europe is increasing, chronic diseases will continue to place a significant pressure on national budgets.

Chronic diseases also cost society a lot because they lower wages, the number of people who work, and the amount of work they do. They also increase early retirement, high job turnover, and disability. Treatment costs for some chronic diseases are also rapidly rising, particularly for late-stage cancer treatment. Demand for costly health-care interventions is expected to rise significantly in Europe over the medium term, despite slowing economic growth and stagnant national health-care budgets.

The co-existence of multiple chronic diseases in one person, known as multimorbidity, is also becoming more common as people get older. More than 50 million people in Europe have multiple chronic diseases, either due to random co-occurrence, a possible shared underlying risk profile, or disease development synergies. There is a direct correlation between the number of comorbid diseases a patient has and the overall treatment and care costs for that patient.

Regional Analysis

The region is segmented on the basis of countries into Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, and Rest of Europe. The Europe clinical trial imaging market is driven by things like the growing number of older people and the rise of chronic diseases like Parkinson's, Huntington's, and Alzheimer's. These things are also driving the adoption of clinical trials in this region. Also, research labs are looking for ways to cut costs, which is why imaging is being used more and more in clinical trials. In the European Union, approximately 4,000 clinical trials of medicines are approved each year (EU). The vast majority of these studies are carried out in the countries of Western Europe, despite the fact that there are fewer clinical trials of medicines being carried out in this part of the world.

Segmental Analysis

The Europe clinical trial imaging market is divided into services and software based on product and service. It is divided into modality segments such as computed tomography, magnetic resonance imaging, echocardiography, nuclear medicine, positron emission tomography, X-ray, ultrasound, optical coherence tomography, and others. Further, it is divided into oncology, neurology, endocrinology, cardiology, dermatology, haematology, and others on the basis of application. Further division is on the basis of end users into pharmaceutical and biotechnology companies, contract research organisations, academic and government research institutes, medical device manufacturers, and others.

Recent Developments

• 2nd February 2022, Energage has recognised Clario as a Top Workplace for the 2022 Top Workplaces USA national awards. Clario is a technology company that provides the leading endpoint technology solutions for clinical trials.
• OXFORD, UK – March 21, 2022 LiverMultiScan cT1, which is an MRI-derived non-invasive tissue biomarker, was found to improve the management of autoimmune hepatitis (AIH) by identifying patients in biochemical remission as well as patients in deep remission who had undetected, active sub-clinical disease that put them at a high risk of disease relapse. This study was the first of its kind and was published in eClinicalMedicine - The Lancet.